Surrogate markers in antiangiogenesis clinical trials

por Davis, D W, McConkey, D J, Abbruzzese, J L, Herbst, R S
Publicado 2003

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer

por van der Vos, K. E., Vis, D. J., Nevedomskaya, E., Kim, Y., Choi, W., McConkey, D., Wessels, L. F. A., van Rhijn, B. W. G., Zwart, W., van der Heijden, M. S.
Publicado 2020

Phase II trial of imatinib mesylate in patients with metastatic melanoma

por Kim, K B, Eton, O, Davis, D W, Frazier, M L, McConkey, D J, Diwan, A H, Papadopoulos, N E, Bedikian, A Y, Camacho, L H, Ross, M I, Cormier, J N, Gershenwald, J E, Lee, J E, Mansfield, P F, Billings, L A, Ng, C S, Charnsangavej, C, Bar-Eli, M, Johnson, M M, Murgo, A J, Prieto, V G
Publicado 2008